You are here

Stable Antimicrobial Formulation of Scopolamine for Multi-dose Vial

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-22-P-0005
Agency Tracking Number: C212-004-0035
Amount: $167,489.52
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD212-004
Solicitation Number: 21.2
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-02-14
Award End Date (Contract End Date): 2022-08-13
Small Business Information
737 Concord Ave
Cambridge, MA 02138-1002
United States
DUNS: 080316838
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Madeline Vara
 (617) 621-8500
Business Contact
 Philip Graf
Phone: (617) 621-8500
Research Institution

Recent efforts to improve treatment for nerve agent poisoning include the development of a scopolamine hydrobromide injectable as an anticholinergic. A scopolamine injectable would add an extremely beneficial capability to the warfighter kit, however, incorporation of single-use vials represents a substantial logistical burden in the field. Co-formulation of the scopolamine injectable with a suitable and stable preservative would render the therapeutic safe for packaging and use in a multi-dose vial format, substantially reducing the burden on the warfighter while enhancing the medical capabilities in the field. However, such a formulation has not been demonstrated. We propose to develop a stable and antimicrobial formulation of scopolamine hydrobromide that is compatible with multi-dose vial requirements. The formulation will meet USP and FDA requirements for antimicrobial activity while maintaining therapeutic efficacy, resulting in a product that has a shelf-life of at least 2 years and a use life once punctured of at least 28 days.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government